News - 14 May 2010
Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company’s innovative work to develop a stable liquid formulation...
News - 2 Oct 2009
Advanced Liquid Logic announced today that it has received a large, four-year contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for...
News - 8 Apr 2008
NanoViricides, Inc., said that preliminary animal trials of the Company’s HIV therapeutic candidates have begun at a BioSafety Level 3 (BSL-3) Laboratory facility in Boston, MA. The initial...
News - 28 Jun 2013
Reportlinker.com announces that a new market research report is available in its catalogue: Bioinspired and Nanoengineered Surfaces: Technologies, Applications and Global Markets
News - 19 Jul 2010
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel...
News - 13 Jul 2010
Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week’s 7th International...
News - 10 Feb 2009
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Antiviral Therapeutics - Technologies, Markets and Companies" to their offering.
News - 25 Sep 2015
Whether triggered by cats, bees, pollen or mites, allergies are on the rise. And the bad news doesn't stop there. The only current therapy that treats their causes is allergen-specific...
News - 27 Aug 2012
A nanoparticle synthesized by researchers at Rice University and assessed in conjunction with Baylor College of Medicine (BCM) holds great promise in emergency treatment of brain injury.
News - 14 Jun 2012
The Querrey Simpson Charitable Foundation has gifted $10 million to Northwestern University to open a center for carrying out research in the field of regenerative nanomedicine. The facility will be...